Q1 2024 Earnings Estimate for Alpine Immune Sciences, Inc. Issued By Wedbush (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) – Equities researchers at Wedbush lifted their Q1 2024 earnings per share estimates for shares of Alpine Immune Sciences in a report issued on Thursday, April 11th. Wedbush analyst R. Driscoll now expects that the biotechnology company will earn ($0.45) per share for the quarter, up from their prior estimate of ($0.48). Wedbush has a “Neutral” rating on the stock. The consensus estimate for Alpine Immune Sciences’ current full-year earnings is ($1.74) per share. Wedbush also issued estimates for Alpine Immune Sciences’ Q2 2024 earnings at ($0.45) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.84) EPS, FY2025 earnings at ($1.95) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($2.58) EPS and FY2028 earnings at ($1.17) EPS.

ALPN has been the topic of a number of other reports. Royal Bank of Canada reissued a “sector perform” rating and set a $65.00 price objective (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Morgan Stanley restated an “equal weight” rating and set a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. TD Cowen restated a “hold” rating on shares of Alpine Immune Sciences in a research report on Tuesday. Guggenheim started coverage on Alpine Immune Sciences in a research report on Tuesday, April 9th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, Oppenheimer reiterated an “outperform” rating and issued a $44.00 price objective (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alpine Immune Sciences presently has a consensus rating of “Hold” and an average price target of $50.33.

Alpine Immune Sciences Trading Up 0.1 %

Shares of NASDAQ ALPN opened at $64.50 on Monday. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of -100.78 and a beta of 1.14. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.57. The stock’s 50-day moving average is $37.92 and its 200 day moving average is $23.86.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. The firm had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ALPN. Decheng Capital LLC purchased a new position in shares of Alpine Immune Sciences in the 4th quarter valued at approximately $135,007,000. Decheng Capital Management III Cayman LLC purchased a new position in shares of Alpine Immune Sciences in the 3rd quarter valued at approximately $76,810,000. Franklin Resources Inc. purchased a new position in shares of Alpine Immune Sciences in the 4th quarter valued at approximately $23,260,000. Vanguard Group Inc. lifted its stake in shares of Alpine Immune Sciences by 51.5% in the 4th quarter. Vanguard Group Inc. now owns 2,234,767 shares of the biotechnology company’s stock valued at $42,595,000 after purchasing an additional 759,888 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of Alpine Immune Sciences by 46.9% in the 2nd quarter. BlackRock Inc. now owns 2,281,692 shares of the biotechnology company’s stock valued at $23,456,000 after purchasing an additional 728,772 shares during the period. Hedge funds and other institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.